FDA Adverse Event Injury Summary report: N

INFUSE BONE GRAFT

MDR report key: 2333258 · Received November 11, 2011

Report

Report Number
1030489-2011-01459
Event Type
Injury
Date Received
November 11, 2011
Report Date
October 14, 2011
Manufacturer
MEDTRONIC SOFAMOR DANEK USA, INC
Product Code
NEK
PMA / PMN Number
P000058
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
KY, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

LITERATURE ARTICLE CITATION: GLASSMAN ET AL. COMPLICATIONS WITH RECOMBINANT HUMAN BONE MORPHOGENIC PROTEIN-2 IN POSTEROLATERAL SPINE FUSION A CONSECUTIVE SERIES OF 1037 CASES. SPINE 2011; 36: 1849-1854. (B)(4). NEITHER THE DEVICE NOR FILMS OF APPLICABLE IMAGING STUDIES WERE RETURNED TO THE MANUFACTURER FOR EVALUATION. THEREFORE, WE ARE UNABLE TO DETERMINE THE DEFINITIVE CAUSE OF THE REPORTED EVENT. A REVIEW OF THE CERTIFICATES OF ANALYSIS AND PACKING LIST FOR THE INFUSE BONE GRAFT WAS NOT POSSIBLE WITHOUT ADDITIONAL DEVICE INFORMATION. MULTIPLE PRODUCTS WERE IMPLANTED DURING THE PROCEDURE. ALTHOUGH IT IS UNKNOWN IF ANY OF THE DEVICES CONTRIBUTED TO THE REPORTED EVENT, WE ARE FILING THIS MDR FOR NOTIFICATION PURPOSES.

Description of Event or Problem · 1

IT WAS REPORTED IN A LITERATURE PUBLICATION THAT MEDICAL RECORDS FOR A CONSECUTIVE SERIES OF 1037 PATIENTS WHO UNDERWENT POSTEROLATERAL SPINE FUSION USING RHBMP-2 WERE REVIEWED. THE 1037 PATIENTS IN THIS SERIES INCLUDED 637 FEMALES AND 400 MALES WITH A MEAN AGE OF 58.4 YEARS (RANGE: 18-90 YEARS). MEAN NUMBER OF SURGICAL LEVELS FUSED WAS 1.8 (RANGE: 1-5 LEVELS). ADDITIONAL GRAFT MATERIAL OR FILLERS INCLUDED LOCAL BONE IN 77.5% OF CASES, ICBG IN 35.4% OF CASES AND ALLOGRAFT BONE IN 33.6% OF CASES. LESS COMMONLY USED WERE DEMINERALIZED BONE MATRIX AND CERAMIC. POST-OPERATIVELY, 2 PATIENTS HAD ACUTE RENAL FAILURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 INFUSE BONE GRAFT FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET NEK MEDTRONIC SOFAMOR DANEK USA, INC NA UNK

Patients

Seq Age Sex Outcome Treatment
1 00058 YR Required Intervention